EUCTR2010-018300-85-DK进行中（未招募）不适用
Double-blind, randomised, placebo-controlled, parallel-group phase II study to evaluate the effect of oral ibodutant in irritable bowel syndrome with diarrhoea (IBS-D) - The Iris-2 Study. - IRIS-2
Menarini Ricerche S.p.A.0 个研究点目标入组 1,220 人开始时间: 2010年6月25日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients meeting the following criteria will be eligible for entry into the study and start the run-in period:
- •1. Male or female patients aged 18 - 70 years with a clinical diagnosis of IBS-D according to the following symptom-based criteria as per Rome III modular questionnaire criteria:
- •- Recurrent abdominal pain or discomfort for at least 3 days per month in the last 3 months associated with at least 2 of the following characteristics: a) improvement with defecation; b) onset associated with a change in the frequency of stool; c) onset associated with a change in form (appearance) of stool.
- •- Symptom-onset at least 6 months prior to diagnosis.
- •- Loose or watery stools at least 25% of the time in the last 3 months AND hard or lumpy stools less than 25% of the time in the last 3 months.
- •- Additional criterion: More than 3 bowel movements per day at least 25% of the time in the last 3 months.
- •2. For patients older than 50 years OR patients with positive family history of colorectal cancer: Normal results from colonoscopy or flexible sigmoidoscopy performed within the last 5 years and after the onset of IBS symptoms, and completed before Screening (Day -14).
- •3. Mentally competent, able to give written informed consent prior to study entry and compliant to undergo all visits and procedures scheduled in the study.
- •4. For women of childbearing potential: Use of a highly effective contraceptive method with a failure rate <1% per year throughout the entire study period and up to 30 days post-treatment. Oral contraceptives are allowed provided that they have not been changed in the previous 6 months.
- •5. Normal physical examination or without clinically relevant abnormalities.
- •Additional Inclusion Criteria at Randomisation (after a 2-week treatment-free run-in period with symptom-collection by IVRS/IWRS diary)
- •Patients’ diary records during the run-in period showing:
- •- at least 25% of the bowel movements with loose or watery (Bristol Stool Scale 6 or 7) consistency AND less than 25% of bowel movements with hard or lumpy (Bristol Stool Scale 1 or 2) consistency,
- •- at least one bowel movement on each day,
- •- weekly average of at least 3 bowel movements per day (during both weeks of the run-in period),
- •- abdominal pain/discomfort of at least moderate (grade 2) severity at least 3 days per week (during both weeks of the run-in period).
- •Adequate compliance with the IVRS/IWRS diary recording procedure (> 75% of the nominal daily entry expected during both weeks of the run-in period).
- •No use of prohibited concurrent medication. NOTE: No short-term use of the antidiarrhoeal loperamide is allowed during the run-in period.
- •No clinically relevant abnormalities in laboratory findings and/or 12-lead ECG performed at Screening.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients will not be eligible to participate in the study if they meet ANY of the following exclusion criteria:
- •1. Organic abnormalities of the GI tract, including history of colonic or major abdominal surgery, i.e. stomach, small/large bowel, or large vessel abdominal surgery (except appendicectomy, hysterectomy, cholecystectomy, caesarean section, or laparoscopic surgery), current or previous diagnosis of neoplasia (except non-GI neoplasia in complete remission = 5 years), inflammatory bowel diseases, symptomatic gallbladder stone disease, complicated diverticulosis (i.e. diverticulitis), ectopic endometriosis.
- •NOTE: Patients with alarm signs (e.g. fever, rectal bleeding, unintentional weight loss, anaemia) deserve special consideration to exclude any organic GI disease.
- •2. History of gluten enteropathy.
- •3. Lactose intolerance as assessed by response to diet.
- •4. History of positive tests for ova or parasites, or occult blood in the stool in the previous 6 months.
- •5. Previous diagnosis of diabetes mellitus (either type 1 or 2).
- •6. Unstable medical condition; i.e. patients for which concurrent diseases may compromise the efficacy and safety assessments as required in the study AND/OR require change in concomitant medication. NOTE: Thyroid hormone replacement therapy should be stable for at least the last 2 months.
- •7. Major psychiatric, neurological, or cardiovascular disorders, or uncontrolled metabolic disease.
- •8. Relevant changes in dietary habits, lifestyle, or exercise regimen in the previous 2 months.
- •NOTE: dietary habits, lifestyle and exercise regimen must be maintained for the duration of the study
- •9. Use of prohibited concurrent medication within 7 days prior to Screening, namely:
- •- Antimuscarinic drugs.
- •- Drugs enhancing GI motility such as prokinetic drugs (e.g. metoclopramide, cisapride, domperidone) or laxatives.
- •- Analgesic drugs (opioids or non-steroidal anti-inflammatory drugs). NOTE: Short term use of paracetamol is allowed for max 2 consecutive days.
- •- Antidepressants. NOTE: The use of a single antidepressants is only allowed when the drug type and its dose regimen has not been changed in the previous 6 months.
- •- Benzodiazepines. NOTE: The use of a single benzodiazepine is only allowed when it is administered as sleep-inducer and the drug type and its dose regimen has not been changed in the previous 6 months.
- •- Other medication for IBS. NOTE: The antidiarrhoeal loperamide must be discontinued 3 days prior to Screening.
- •10. Pregnancy or breastfeeding.
- •11. Hypersensitivity to the drug excipients.
- •12. Patients not able to understand or collaborate throughout the study.
- •13. Participation in other clinical studies in the previous 4 weeks.
研究者
相似试验
进行中（未招募）
不适用
Double-blind, randomised, placebo-controlled, parallel group pilot study to evaluate the efficacy and safety of oral administration of Nepadutant in infant colic babies not responder to conventional treatments - NOCRY-aMedDRA version: 9.1Level: LLTClassification code 10061247Infant colicEUCTR2010-022706-41-ITMENARINI RICERCHE S.P.A.
进行中（未招募）
不适用
Double-blind, randomised, placebo-controlled, parallel-group phase II study to evaluate the effect of oral ibodutant in irritable bowel syndrome with diarrhoea (IBS-D) - The Iris-2 Study. - IRIS-2Irritable bowel syndrome with diarrhoea (IBS-D)MedDRA version: 14.0Level: LLTClassification code 10060849Term: Diarrhoea predominant irritable bowel syndromeSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2010-018300-85-DEMenarini Ricerche S.p.A.1,220
进行中（未招募）
不适用
Double-blind, randomised, placebo-controlled, parallel group study to evaluate the efficacy and safety of oral administration of Nepadutant in infant colic - nocryInfant ColicEUCTR2009-018218-21-DEMenarini Ricerche S.p.A.120
进行中（未招募）
不适用
Double-blind, randomised, placebo-controlled, parallel-group phase II study to evaluate the effect of oral ibodutant in irritable bowel syndrome with diarrhoea (IBS-D). - IRIS-2Irritable bowel syndrome with diarrhoea (IBS-D).MedDRA version: 12.1Level: LLTClassification code 10060845Term: Diarrhea predominant irritable bowel syndromeEUCTR2010-018300-85-ITMENARINI RICERCHE S.P.A.900
进行中（未招募）
不适用
Double-blind, randomised, placebo-controlled, parallel-group phase II study to evaluate the effect of oral ibodutant in irritable bowel syndrome with diarrhoea (IBS-D) - The Iris-2 Study. - IRIS-2EUCTR2010-018300-85-SEMenarini Ricerche S.p.A.1,220